source
- FDA’s AI push faces uncertainty after key leaders departThe FDA has been pushing artificial intelligence across the agency, unveiling a large-language-model tool called Elsa to help draft and summarize review reports and announcing plans to use agentic…
- Argenx to buy Forte Biosciences for up to $2.2 billion, adding experimental CD122 drug FB102Argenx announced it will acquire Forte Biosciences in a transaction valued at up to $2.2 billion. The purchase price is set at $77 per Forte share, roughly a 41% premium to the previous closing pr…